---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009065"
form_type: "8-K"
ticker: "NASC"
cik: "0001509957"
company_name: "Can B Corp"
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:35:34.725276+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Can B Corp. subsidiary Nascent Pharma acquires two cannabis liquid formulation patents valued at $122M

## Summary
- Nascent Pharma, 67% owned by Can B, acquired US patents 9,730,911 and 10,555,928 covering liquid cannabis formulations including beverages, tinctures, vape pens, and capsules.
- Independent 2020 valuation set patent value at $122M, applying a 90% discount on projected income streams through August 2034.
- Nascent agreed to pay prior patent owner's creditors 5% of Can B's share of Nascent revenues until aggregate $10M paid.
- Consulting agreement with inventor entitles consultant to 50% of distributions Can B receives from Nascent.
- Can B warns no assurance patents will generate revenue or achieve the $122M valuation.

## SEC filing metadata
- accession: 0001493152-24-009065
- form_type: 8-K
- ticker: NASC
- cik: 0001509957
- company_name: Can B Corp
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509957/000149315224009065/0001493152-24-009065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509957/000149315224009065/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009065
- JSON: https://secwatch.observer/filing/0001493152-24-009065.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.